Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Genevieve Boland

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Cancer Immunology Research|December 7, 2017
A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic MelanomaJeffrey S Weber, Mario Sznol, Ryan J Sullivan, et al.
Science Translational Medicine|May 31, 2023
Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomasNobuhiko Kanaya, Yohei Kitamura, Maria Lopez Vazquez, et al.
Journal for Immunotherapy of Cancer|February 26, 2021
Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohortXue Bai, Michelle Kim, Gyulnara Kasumova, et al.
Biorxiv : the Preprint Server for Biology|September 26, 2025
YAP1 drives aggressive and therapy resistant state in melanoma through reprogramming the chromatin and regulating immune evasive programsNana Chen, Gracia Bonilla, Abdullah Ai Emran, et al.
JAMA Network Open|May 22, 2026
Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor RecipientsGuihong Wan, Nga Nguyen, Charles Lu, et al.
Medrxiv : the Preprint Server for Health Sciences|July 16, 2025
Effect of systemic glucocorticoid immunosuppression timing, dose, and duration on overall survival among immune checkpoint inhibitor recipients: a retrospective multicohort studyGuihong Wan, Nga Nguyen, Charles Lu, et al.
Future Oncology (London, England)|January 25, 2022
PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrenceAlexander Mm Eggermont, Paolo A Ascierto, Nikhil I Khushalani, et al.
The Oncologist|April 15, 2021
Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19Isaac A Klein, Shoshana M Rosenberg, Kerry L Reynolds, et al.
Biorxiv : the Preprint Server for Biology|September 4, 2024
Cell states and neighborhoods in distinct clinical stages of primary and metastatic esophageal adenocarcinomaJosephine Yates, Camille Mathey-Andrews, Jihye Park, et al.
Cell Reports. Medicine|June 11, 2025
Cell states and neighborhoods in distinct clinical stages of primary and metastatic esophageal adenocarcinomaJosephine Yates, Camille Mathey-Andrews, Jihye Park, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Cancer Immunology Research|December 7, 2017
A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic MelanomaJeffrey S Weber, Mario Sznol, Ryan J Sullivan, et al.
Science Translational Medicine|May 31, 2023
Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomasNobuhiko Kanaya, Yohei Kitamura, Maria Lopez Vazquez, et al.
Journal for Immunotherapy of Cancer|February 26, 2021
Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohortXue Bai, Michelle Kim, Gyulnara Kasumova, et al.
Biorxiv : the Preprint Server for Biology|September 26, 2025
YAP1 drives aggressive and therapy resistant state in melanoma through reprogramming the chromatin and regulating immune evasive programsNana Chen, Gracia Bonilla, Abdullah Ai Emran, et al.
JAMA Network Open|May 22, 2026
Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor RecipientsGuihong Wan, Nga Nguyen, Charles Lu, et al.
Medrxiv : the Preprint Server for Health Sciences|July 16, 2025
Effect of systemic glucocorticoid immunosuppression timing, dose, and duration on overall survival among immune checkpoint inhibitor recipients: a retrospective multicohort studyGuihong Wan, Nga Nguyen, Charles Lu, et al.
Future Oncology (London, England)|January 25, 2022
PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrenceAlexander Mm Eggermont, Paolo A Ascierto, Nikhil I Khushalani, et al.
The Oncologist|April 15, 2021
Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19Isaac A Klein, Shoshana M Rosenberg, Kerry L Reynolds, et al.
Biorxiv : the Preprint Server for Biology|September 4, 2024
Cell states and neighborhoods in distinct clinical stages of primary and metastatic esophageal adenocarcinomaJosephine Yates, Camille Mathey-Andrews, Jihye Park, et al.
Cell Reports. Medicine|June 11, 2025
Cell states and neighborhoods in distinct clinical stages of primary and metastatic esophageal adenocarcinomaJosephine Yates, Camille Mathey-Andrews, Jihye Park, et al.
Pageof 5